drugset
drugset / Trial / NCT01757873

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

NCT01757873 ↗

Phase 2 Completed 144 enrolled Zalicus
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will compare Z160 and placebo in patients with Postherpetic Neuralgia for safety and efficacy for a period of 6 weeks.

Timeline

Start
2012-12
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Z160 Small molecule 375 mg —

Indications

postherpetic neuralgia